These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 24061081)

  • 1. Pharmacotherapy: Cardiovascular safety of antihyperglycaemic drugs in patients with type 2 diabetes mellitus.
    Greenhill C
    Nat Rev Endocrinol; 2013 Nov; 9(11):625. PubMed ID: 24061081
    [No Abstract]   [Full Text] [Related]  

  • 2. Diabetes: Cardiovascular safety of 'gliptin' therapy.
    Lim GB
    Nat Rev Cardiol; 2013 Nov; 10(11):616. PubMed ID: 24042219
    [No Abstract]   [Full Text] [Related]  

  • 3. Saxagliptin, alogliptin, and cardiovascular outcomes.
    Standl E
    N Engl J Med; 2014 Jan; 370(5):483. PubMed ID: 24476445
    [No Abstract]   [Full Text] [Related]  

  • 4. [New antihyperglycemic drugs. Examination of cardiovascular outcomes with alogliptin versus standard of care (EXAMINE) and saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI 53)].
    Gallwitz B; Nitschmann S
    Internist (Berl); 2014 Jul; 55(7):859-62. PubMed ID: 24969610
    [No Abstract]   [Full Text] [Related]  

  • 5. Gliptins - do they increase cardiovascular risk or benefit?
    Doggrell SA; Dimmitt SB
    Expert Opin Drug Saf; 2014 May; 13(5):675-80. PubMed ID: 24684173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Saxagliptin, alogliptin, and cardiovascular outcomes.
    White WB; Zannad F
    N Engl J Med; 2014 Jan; 370(5):484. PubMed ID: 24482824
    [No Abstract]   [Full Text] [Related]  

  • 7. Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome.
    Derosa G; Maffioli P
    N Engl J Med; 2016 Mar; 374(11):1095. PubMed ID: 26981947
    [No Abstract]   [Full Text] [Related]  

  • 8. Is the Use of DPP-4 Inhibitors Associated With an Increased Risk for Heart Failure? Lessons From EXAMINE, SAVOR-TIMI 53, and TECOS.
    Schernthaner G; Cahn A; Raz I
    Diabetes Care; 2016 Aug; 39 Suppl 2():S210-8. PubMed ID: 27440835
    [No Abstract]   [Full Text] [Related]  

  • 9. New Treatments for Type 2 Diabetes Mellitus and Cardiovascular Disease. The Revolution Has Begun.
    Simó R; Hernández C
    Rev Esp Cardiol (Engl Ed); 2016 Nov; 69(11):1005-1007. PubMed ID: 27659856
    [No Abstract]   [Full Text] [Related]  

  • 10. New oral hypoglycaemics fail to show cardiovascular benefits.
    Cohen D
    BMJ; 2013 Sep; 347():f5458. PubMed ID: 24014343
    [No Abstract]   [Full Text] [Related]  

  • 11. Dipeptidyl peptidase-4 inhibitors and cardiovascular safety.
    Davis TM
    Med J Aust; 2014 May; 200(8):450-1. PubMed ID: 24794596
    [No Abstract]   [Full Text] [Related]  

  • 12. Saxagliptin, alogliptin, and cardiovascular outcomes.
    Scirica BM; Braunwald E; Bhatt DL
    N Engl J Med; 2014 Jan; 370(5):483-4. PubMed ID: 24476444
    [No Abstract]   [Full Text] [Related]  

  • 13. [The TECOS, EXAMINE and SAVOR studies--how do they differ and what are their outcomes?].
    Špinar J; Špinarová L; Vítovec J
    Vnitr Lek; 2015 Nov; 61(11):976-83. PubMed ID: 26652787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ACP Journal Club. In at-risk patients with type 2 diabetes, saxagliptin and placebo did not differ for CV events.
    Morey-Vargas OL; Montori VM
    Ann Intern Med; 2014 Jan; 160(2):JC8-9. PubMed ID: 24445719
    [No Abstract]   [Full Text] [Related]  

  • 15. Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
    White WB; Cannon CP; Heller SR; Nissen SE; Bergenstal RM; Bakris GL; Perez AT; Fleck PR; Mehta CR; Kupfer S; Wilson C; Cushman WC; Zannad F;
    N Engl J Med; 2013 Oct; 369(14):1327-35. PubMed ID: 23992602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In AF or VTE, warfarin dosing by genotype improved time in therapeutic range but not clinical outcomes.
    Dunn A
    Ann Intern Med; 2014 Mar; 160(6):JC9. PubMed ID: 24638187
    [No Abstract]   [Full Text] [Related]  

  • 17. New drugs improve glycemic control in type 2 diabetes, but improving heart health remains elusive.
    Mitka M
    JAMA; 2013 Oct; 310(14):1435-6. PubMed ID: 24104360
    [No Abstract]   [Full Text] [Related]  

  • 18. Lessons from SAVOR and EXAMINE: some important answers, but many open questions.
    Schernthaner G; Sattar N
    J Diabetes Complications; 2014; 28(4):430-3. PubMed ID: 24713467
    [No Abstract]   [Full Text] [Related]  

  • 19. Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials.
    Mannucci E; Monami M
    Adv Ther; 2017 Jan; 34(1):1-40. PubMed ID: 27844335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An update on the 'gliptins'.
    Drug Ther Bull; 2016 Dec; 54(12):138-141. PubMed ID: 27979881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.